REGENXBIO Inc. (NASDAQ:RGNX) Short Interest Update

REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totalling 6,300,000 shares, an increase of 21.9% from the April 30th total of 5,170,000 shares. Currently, 14.6% of the shares of the company are sold short. Based on an average trading volume of 1,110,000 shares, the short-interest ratio is presently 5.7 days.

REGENXBIO Price Performance

RGNX traded up $1.25 during midday trading on Friday, reaching $9.61. 1,911,387 shares of the company's stock were exchanged, compared to its average volume of 920,582. The stock has a market capitalization of $482.04 million, a PE ratio of -1.91 and a beta of 1.11. The business's 50-day moving average price is $8.10 and its 200 day moving average price is $7.94. REGENXBIO has a 1-year low of $5.04 and a 1-year high of $15.36.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.41 by ($0.29). The business had revenue of $89.01 million for the quarter, compared to analyst estimates of $105.35 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. As a group, analysts expect that REGENXBIO will post -4.84 EPS for the current fiscal year.

Insider Activity

In other news, Director Kenneth T. Mills sold 20,602 shares of REGENXBIO stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $7.91, for a total value of $162,961.82. Following the sale, the director now owns 475,103 shares of the company's stock, valued at $3,758,064.73. The trade was a 4.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 12.79% of the company's stock.

Hedge Funds Weigh In On REGENXBIO

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC acquired a new position in shares of REGENXBIO in the first quarter valued at approximately $35,000. Brooklyn Investment Group raised its position in shares of REGENXBIO by 163.7% in the first quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company's stock valued at $40,000 after buying an additional 3,466 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of REGENXBIO in the fourth quarter valued at approximately $54,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of REGENXBIO in the fourth quarter valued at approximately $79,000. Finally, Laurion Capital Management LP acquired a new position in shares of REGENXBIO in the fourth quarter valued at approximately $79,000. Institutional investors and hedge funds own 88.08% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Wall Street Zen upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a research note on Friday, March 7th. Raymond James assumed coverage on shares of REGENXBIO in a research note on Friday, February 7th. They issued an "outperform" rating and a $27.00 price objective for the company. HC Wainwright reduced their price objective on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, March 17th. Morgan Stanley raised their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a research note on Friday, March 14th. Finally, Leerink Partners set a $24.00 price objective on shares of REGENXBIO in a research note on Tuesday, March 18th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, REGENXBIO presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.63.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.